Deutsche Bank Warns Novo Nordisk (NYSE: NVO) ZEUS Trial Offers Little Upside As $30 Billion Patent Cliff Approaches

Deutsche Bank Warns Novo Nordisk (NYSE: NVO) ZEUS Trial Offers Little Upside As $30 Billion Patent Cliff Approaches

Deutsche Bank has set a price target of DKK290 on Novo Nordisk (NYSE: NVO), representing just 3.6% upside from the last closing price of DKK280.10, while maintaining a hold rating on the stock. The bank expects the company’s pending ZEUS trial to miss, though it acknowledges low confidence in that prediction, pointing to genuine uncertainty surrounding the trial’s outcome. The ZEUS trial is testing ziltivekimab, known as zilte, a drug being deve…